Nu-Med Plus, Inc. Raises Funding for Completion of Inhaled Nitric Oxide (INO) Clinical Unit

SALT LAKE CITY, UT--(Marketwired - Dec 8, 2015) - Nu-Med Plus, Inc. (OTCBB: NUMD), a medical device development company, announced it has received interim funding thru the guidance of Smith Corporate Services to accelerate the completion of its INO clinical device designed for low cost use in out-patient and medical office settings.

Nitric Oxide (NO) is an essential biological gas which is currently being used for congenital pulmonary hypoplasia and neonatal hypoxia therapy. Contemporary research is being done for additional applications involving the therapeutic need for vasodilation and increased delivery of oxygen to diseased and injured tissues. The smaller multi-dose Inhaled Nitric Oxide clinical device will have the capability to deliver high-purity INO in single-dose treatments, using our proprietary formulation. The emphasis is to generate controlled-flow of INO for internal and external therapies with integrating accessories for availability in emergency rooms and urgent care facilities, medical and chiropractic offices, convalescent and nursing homes, and for emergency response teams for treatment of various trauma injuries.

Jeff Robins, President and CEO of Nu-Med Plus, Inc., commented, "We are very excited about the amazing interest and attention that our company is experiencing and trust that with this additional capital the company can move quickly toward redefining the INO arena with the completion of our INO clinical device using our conversion technology, which will allow for single treatments for internal and external therapies in numerous medical facilities and services."

About Nu-Med Plus, Inc.

Nu-Med Plus, Inc. designs, develops and markets innovative medical devices for use in patient treatment. Initial research and product development has been in the delivery of nitric oxide gas for therapeutic use. For more information please visit www.nu-medplus.com.

Forward-Looking Statements
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's ability to complete proposed private placement financing. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.